Skip to main content
. Author manuscript; available in PMC: 2011 Jun 15.
Published in final edited form as: J Immunol. 2010 May 14;184(12):6695–6708. doi: 10.4049/jimmunol.0903130

FIGURE 3.

FIGURE 3

DC directed CTLA-4 engagement in pre-diabetic NOD mice delays hyperglycemia. Eight-week (A) and 12-week (B) old euglycemic female NOD mice were left untreated or treated with β-cell Ag -pulsed or non-pulsed control or anti-CTLA-4 Ab coated DCs (5×106 cells/mouse) twice 15-days apart. Mice were bled every week for up to 30 weeks of age to monitor blood glucose levels. Mice that showed glucose levels >250 mg/dl for two consecutive weeks were considered diabetic. Eight to 10 mice were included in each group, and the experiment was repeated with a similar number of mice/group. Values from each group were compared to that of untreated or Ag-pulsed control DC treated group using log-rank test and statistically significant values are shown. Statistically significant values obtained when Ag-pulsed anti-CTLA-4 Ab-DC recipient group was compared with untreated group (p=0.009 of panel A and p=0.013 of panel B) and Ag-pulsed control DC recipient group (p=0.021 of panel A and p=0.032 of panel B) are shown.